Exclusive Speaker Interview with Achim Kless, Pain Genetics Lead from Eli Lilly & Company Ahead of Pain Therapeutics
SMi Group Reports: Achim Kless, Pain Genetics Lead from Eli Lilly & Company gives an exclusive interview ahead of SMi’s 21st Annual Pain Therapeutics Virtual Conference, taking place 10-11 May 2021.
London, United Kingdom, April 10, 2021 --(PR.com)-- Ahead of the 21st Annual Pain Therapeutics Conference, SMi Group had the pleasure of catching up with Achim Kless, pain genetics lead, Eli Lilly and Co to find out about Achim’s work, vital topics being addressed in his presentation, thoughts on the most innovative therapy and on how the pain industry is responding to the opioid crisis and what the biggest growth area will be in 2021. The conference will convene on the 10th and 11th May 2021.
Interested parties can attend the conference at £499 for pharmaceutical and biotechnology firms, and £999 for vendors and commercial firms at http://www.pain-therapeutics.co.uk/PR4.
Achim will bring with him a wealth of experience with career highlights such as, a Ph.D from the University of Rostock, designing novel drugs where 3 of them have reached clinical trial status and being Scientific Director at the department of translational science and intelligence. Finally, as pain genetics lead at Eli Lilly and Co, Achim is currently researching the fields of molecular genetics and non-coding RNA for the discovery of novel pain targets.
An excerpt of his much-anticipated interview is below, of which the full interview can be found in the "download centre" on http://www.pain-therapeutics.co.uk/PR4.
The Pain Therapeutics field has advanced greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
“Especially the growing applications of CRISPR/CAS and gene editing allow to quickly validate novel pain targets using human cell lines. Further novel modalities like antibody conjugates and siRNA technologies enlarge the space for formerly inaccessible pain targets. Additionally, the number of GWAS cohorts like FinnGen with pain relevant phenotypes is constantly growing and results are a great source for the identification of novel targets.”
What would you say is the biggest and the most innovative therapy that is currently driving the market?
“Gene therapies especially within the area of monogenic rare diseases will lead us to a better understanding of pain pathophysiology in specific indications that can inform selection of targets and development for broader indications like chronic pain or peripheral polyneuropathies.”
Achim Kless will be speaking and looking at the future of pain therapeutics and presenting on Exploring pain genetics in rare diseases:
• From GWAS results to novel pain targets
• Exploring rare variants in pain target discovery
• Pain phenotypes across traits
• Future of drug development for rare diseases
As Europe's leading Pain Therapeutics Conference, this is an essential event for those in the field.
The full two-day programme, speaker line-up and brochure can be viewed online at http://www.pain-therapeutics.co.uk/PR4.
Proudly sponsored by: Transpharmation and MD Biosciences
To join Pain Therapeutics Conference as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 21st Annual Pain Therapeutics Conference
10 – 11 May 2021
Virtual Conference: Online Access Only
http://www.pain-therapeutics.co.uk/PR4
#SMiPain
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.
Interested parties can attend the conference at £499 for pharmaceutical and biotechnology firms, and £999 for vendors and commercial firms at http://www.pain-therapeutics.co.uk/PR4.
Achim will bring with him a wealth of experience with career highlights such as, a Ph.D from the University of Rostock, designing novel drugs where 3 of them have reached clinical trial status and being Scientific Director at the department of translational science and intelligence. Finally, as pain genetics lead at Eli Lilly and Co, Achim is currently researching the fields of molecular genetics and non-coding RNA for the discovery of novel pain targets.
An excerpt of his much-anticipated interview is below, of which the full interview can be found in the "download centre" on http://www.pain-therapeutics.co.uk/PR4.
The Pain Therapeutics field has advanced greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
“Especially the growing applications of CRISPR/CAS and gene editing allow to quickly validate novel pain targets using human cell lines. Further novel modalities like antibody conjugates and siRNA technologies enlarge the space for formerly inaccessible pain targets. Additionally, the number of GWAS cohorts like FinnGen with pain relevant phenotypes is constantly growing and results are a great source for the identification of novel targets.”
What would you say is the biggest and the most innovative therapy that is currently driving the market?
“Gene therapies especially within the area of monogenic rare diseases will lead us to a better understanding of pain pathophysiology in specific indications that can inform selection of targets and development for broader indications like chronic pain or peripheral polyneuropathies.”
Achim Kless will be speaking and looking at the future of pain therapeutics and presenting on Exploring pain genetics in rare diseases:
• From GWAS results to novel pain targets
• Exploring rare variants in pain target discovery
• Pain phenotypes across traits
• Future of drug development for rare diseases
As Europe's leading Pain Therapeutics Conference, this is an essential event for those in the field.
The full two-day programme, speaker line-up and brochure can be viewed online at http://www.pain-therapeutics.co.uk/PR4.
Proudly sponsored by: Transpharmation and MD Biosciences
To join Pain Therapeutics Conference as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 21st Annual Pain Therapeutics Conference
10 – 11 May 2021
Virtual Conference: Online Access Only
http://www.pain-therapeutics.co.uk/PR4
#SMiPain
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.
Contact
SMi Group
Simi Sapal
+44 (0) 20 7827 6162
http://www.pain-therapeutics.co.uk/PR4
Simi Sapal
+44 (0) 20 7827 6162
http://www.pain-therapeutics.co.uk/PR4
Contact
Categories